Peptides vs TRT: A Safety-Focused Comparison

Key Takeaways

• TRT safety context: The TRAVERSE trial, the largest cardiovascular safety RCT of TRT, found testosterone non-inferior to placebo for major adverse cardiac events in 5,246 hypogonadal men with elevated CV risk. Secondary signals including atrial fibrillation and pulmonary embolism were elevated in the testosterone group [Human RCT].
• Primary TRT risks to monitor: Erythrocytosis (hematocrit elevation above 0.52) is a well-documented hematological risk of TRT; 23% of patients in one retrospective cohort reached hematocrit above 0.50 on therapy.
• Fertility impact: TRT suppresses LH and FSH through HPG axis negative feedback, impairing spermatogenesis; recovery after cessation is possible but not guaranteed.
• Peptide and SERM approaches: Compounded gonadorelin (a GnRH peptide) and compounded enclomiphene (a SERM, not a peptide) have been studied for raising endogenous testosterone while preserving the HPG axis; neither is FDA-approved for this use and long-term clinical outcome data is substantially thinner than for TRT. Kisspeptin is investigational with no FDA-approved indication or commercial product.
• Evidence quality: TRT has extensive Phase 3 RCT and long-term observational data; peptide-based alternatives have Phase 2 trial data at best, with most compounds lacking large long-term safety studies.
• Provider framing: All safety assessments for either approach require individual evaluation. Underlying cause of low testosterone, cardiovascular history, fertility goals, and baseline biomarkers all determine which option a provider can appropriately consider.

Some clinic websites describe testosterone replacement as carrying serious cardiac risks that peptides avoid. Others describe peptide approaches as low-risk alternatives to TRT. Neither framing is accurate. TRT has substantial clinical trial evidence, including the 5,246-person TRAVERSE cardiovascular safety trial, that allows precise characterization of its risk profile. Peptide-based approaches to testosterone optimization have far thinner trial records. Less known risk does not mean less risk. This article covers what the published evidence actually shows for both approaches, graded by evidence quality.

What TRT and Peptide Approaches Are Actually Doing

The pharmacological distinction between testosterone replacement and peptide-based HPG axis stimulation matters before any safety comparison. Testosterone replacement directly supplies exogenous androgen, which suppresses the hypothalamic-pituitary-gonadal (HPG) axis through negative feedback on gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). Endogenous testosterone production falls while exogenous testosterone maintains serum levels. HPG-stimulating approaches include peptide compounds (GnRH analogues like gonadorelin, neuropeptides like kisspeptin) and selective estrogen receptor modulators (enclomiphene, a small-molecule SERM, not a peptide) that signal the axis to produce testosterone endogenously, preserving testicular function and the hormonal cascade. Growth hormone secretagogues (ipamorelin, CJC-1295, sermorelin) operate on an entirely separate axis and do not directly affect testosterone; they are sometimes used alongside TRT or HPG stimulants to address body composition concerns that testosterone alone does not fully resolve.

The evidence quality for each effect described below varies significantly by compound and by the source of data. Effects are graded throughout using the following system: [Human RCT] / [Human observational] / [Animal data] / [Anecdotal/case report].

TRT Safety Profile: What the Evidence Shows

Cardiovascular safety: the TRAVERSE trial

The largest cardiovascular safety RCT of TRT is the TRAVERSE trial, published by Lincoff and colleagues in the New England Journal of Medicine in 2023. The trial enrolled 5,246 hypogonadal men with elevated cardiovascular risk and randomized them to testosterone replacement or placebo for a median 33-month follow-up. The primary composite cardiovascular endpoint (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) occurred in 7.0% of the testosterone group versus 7.3% of the placebo group: a hazard ratio of 0.96 (95% CI, 0.78–1.17), meeting the pre-specified non-inferiority threshold. The evidence grade for this finding is [Human RCT].

That non-inferiority finding for the primary endpoint does not mean the cardiovascular safety profile is completely clean. The TRAVERSE data also showed higher incidence of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group compared to placebo. These secondary signals, though not the primary endpoint, are clinically meaningful and require acknowledgment. Cannarella and colleagues, in a 2024 systematic review and meta-analysis published in the Asian Journal of Andrology, analyzed 4,027 patients from RCTs and 310,288 from observational studies and found that RCT data showed no statistically significant increase in venous thromboembolism risk (OR 1.42; 95% CI 0.22–9.03; P = 0.71), though confidence intervals were wide. Hackett, writing in the World Journal of Men's Health in 2025, contextualized the TRAVERSE results for clinical practice, noting that the non-inferiority finding supports TRT use in appropriately selected hypogonadal men with cardiovascular risk but does not eliminate the need for monitoring. Evidence grade: [Human RCT / Human observational].

A 2026 expert panel position statement by Zitzmann and colleagues, published in Andrology, synthesized the post-TRAVERSE European consensus on TRT cardiovascular safety. The European panel concluded that TRT is not contraindicated in men with hypogonadism and cardiovascular disease when properly managed, but emphasized that individual cardiovascular risk assessment and monitoring remain essential before and during therapy. In the US context, FDA's February 2025 drug safety communication updated testosterone product labeling by removing the generic cardiovascular class warning that had been present since 2015, citing the TRAVERSE non-inferiority finding.

Erythrocytosis: a well-documented hematological risk

Erythrocytosis is an elevation in red blood cell mass, typically defined as hematocrit above 0.52. It is a well-documented hematological adverse effect of TRT. Jones and colleagues, writing in Sex Med Rev in 2015, found that men on TRT had a 315% greater risk of developing erythrocytosis compared to untreated controls. The proposed mechanisms involve three pathways: increased iron bioavailability, elevated erythropoietin production, and direct bone marrow stimulation. Injectable formulations produce the most pronounced hematocrit elevations across delivery methods. Evidence grade: [Human observational].

Neidhart and colleagues, in a 247-patient retrospective study published in Frontiers in Endocrinology in 2025, quantified erythrocytosis prevalence in a real-world TRT cohort: 57% of patients reached hematocrit above 0.46, 23% above 0.50, and 5% above 0.54 during treatment. Baseline hematocrit and body mass index were identified as significant predictors, with 46% of those who reached hematocrit above 0.46 doing so within the first year of therapy. The clinical significance of elevated hematocrit relates primarily to theoretical thrombotic risk; the causal relationship between TRT-induced erythrocytosis and venous thromboembolism has not been definitively established in adequately powered trials. Monitoring hematocrit at baseline and periodically during TRT is standard clinical practice. Evidence grade: [Human observational].

Prostate effects: what the trial data shows

Concerns about TRT and prostate safety have a long clinical history. The 2024 meta-analysis by Xu and colleagues, published in Frontiers in Endocrinology, analyzed 3,461 patients across 28 RCTs and found no statistically significant adverse effects on prostate volume, IPSS, or maximum urinary flow rate, with PSA at the margin of significance (p=0.06). Erectile function improved compared with placebo on the International Index of Erectile Function. [Human RCT] The guideline-level evidence synthesis by Cruickshank and colleagues for the UK National Institute for Health Research, published in Health Technology Assessment in 2024 and covering 35 trials and 5,601 randomized participants, similarly found TRT improved quality of life and sexual function across patient subgroups without evidence of cardiovascular harm in the short-to-medium term. Evidence grade: [Human RCT].

Current evidence does not support TRT as a cause of prostate cancer in hypogonadal men. Monitoring PSA levels before and during TRT remains standard of care for men with prostate risk factors, consistent with prescribing guidelines from De Silva and colleagues, whose authoritative review in Lancet Diabetes and Endocrinology in 2024 defines the clinical criteria for TRT initiation and monitoring.

Fertility suppression: the HPG axis consequence

TRT suppresses the HPG axis through negative feedback, reducing LH and FSH secretion and impairing both testicular testosterone production and spermatogenesis. McBride and Coward, writing in the Asian Journal of Andrology in 2016, reviewed evidence that spontaneous spermatogenesis recovery after TRT cessation is possible but not guaranteed; some patients require clinical intervention with injectable gonadotropins, selective estrogen receptor modulators, or aromatase inhibitors. Stocks and colleagues, publishing in Fertility and Sterility in 2025, studied optimal restoration of spermatogenesis using hCG and FSH after TRT, providing evidence that targeted interventions can accelerate recovery for men who seek to restore fertility. Fertility suppression during TRT is not a theoretical concern. It is a predictable physiological consequence of exogenous androgen administration. Evidence grade: [Human observational / Human RCT].

Peptide-Based Approaches: Evidence and Risk Profile

HPG axis stimulants: gonadorelin and investigational kisspeptin

Gonadorelin is a synthetic GnRH analogue that stimulates LH and FSH release from the pituitary when administered in a pulsatile protocol, preserving the HPG axis cascade rather than replacing it. It is primarily used clinically for hypogonadotropic hypogonadism and for fertility preservation in men on TRT. Gonadorelin acetate was previously FDA-approved (as Factrel for diagnostic use and Lutrepulse for pulsatile administration in hypothalamic amenorrhea) before both products were discontinued; gonadorelin has since been placed on Category 1 of FDA's 503A bulk drug substances list (current status subject to ongoing rulemaking), and is available from licensed compounding pharmacies under Section 503A. It is not FDA-approved for general male hypogonadism management. No large Phase 3 RCT has established gonadorelin as a long-term TRT alternative. Evidence grade for testosterone restoration: [Human observational / limited RCT data].

Kisspeptin is an investigational compound with no FDA-approved indication and no lawful prescribing pathway for hypogonadism outside a registered clinical trial. George and colleagues, publishing in the Journal of Clinical Endocrinology and Metabolism in 2011, demonstrated that kisspeptin-10 potently stimulated LH secretion and increased pulse frequency in healthy men, establishing its mechanistic role as an upstream HPG axis activator. Mills and colleagues published a 32-participant RCT in JAMA Network Open in 2023, reporting that kisspeptin administration produced a greater tumescence response to visual stimuli than placebo at peak response in men with hypoactive sexual desire disorder. Abbara, Clarke and Dhillo, writing in Trends in Molecular Medicine in 2021, reviewed kisspeptin's translational potential across reproductive health applications, noting promising early clinical signals alongside significant remaining evidence gaps. Evidence grade: [Human RCT (small-N); Human observational (mechanism)].

The HPG stimulant approach carries a different risk architecture than TRT. Because these peptides act upstream rather than replacing testosterone, they preserve testicular function and do not predictably cause erythrocytosis or HPG axis suppression. The long-term safety profile of sustained kisspeptin or GnRH analogue administration is not well characterized; those studies have not been completed. Large Phase 3 safety trials for either compound as standalone hypogonadism therapy are absent from the published literature.

Enclomiphene: the selective estrogen receptor modulator approach

Enclomiphene is the trans-isomer of clomiphene. It blocks hypothalamic estrogen receptors to remove inhibitory feedback on GnRH, effectively signaling the axis to increase LH and FSH production. Wiehle and colleagues, in a 2013 Phase 2 pharmacodynamics/pharmacokinetics study in BJU International, reported that 25 mg enclomiphene daily raised mean testosterone to within the normal range in men with secondary hypogonadism, while elevating LH and FSH. This is the opposite of the LH suppression observed with transdermal testosterone. A follow-on randomized Phase 2 trial by Wiehle and colleagues, published in Fertility and Sterility in 2014, demonstrated enclomiphene raised testosterone while preserving sperm counts, in contrast to topical testosterone which raised testosterone but reduced sperm counts. Kim, McCullough and Kaminetsky, in a 2016 Phase III multicenter RCT in BJU International, replicated the testosterone restoration finding in obese hypogonadal men, emphasizing the axis-preservation advantage over replacement therapy. Evidence grade: [Human RCT, Phase 2 and Phase 3 data; no successful Phase 3 trial leading to FDA approval].

Enclomiphene (the trans-isomer of clomiphene) has never been FDA-approved; its developer received FDA Complete Response Letters in 2015 and 2016 and the product was not approved. Enclomiphene is available through compounding pharmacies under Section 503A; the racemic parent compound clomiphene citrate is FDA-approved for female ovulation induction only. Use of compounded enclomiphene for male hypogonadism is prescribing of a non-FDA-approved compounded substance, not off-label use of an approved drug. The most recent systematic review and meta-analysis of clomiphene and enclomiphene RCTs by Hohl and colleagues, published in Archives of Endocrinology and Metabolism in 2025, synthesized the available evidence across 11 trials, confirming testosterone restoration efficacy while noting the absence of Phase 3 data and the need for longer-term safety characterization. Visual disturbances and mood effects are the most frequently noted adverse events in the clomiphene/enclomiphene literature; their frequency in longer-term enclomiphene use specifically is not established from controlled trial data.

GH secretagogues: a different question entirely

Growth hormone secretagogues (ipamorelin, CJC-1295, sermorelin) do not raise testosterone and are not alternatives to TRT for hypogonadism. They stimulate GH and downstream IGF-1 production through pituitary GH receptors or GHRH receptor activation. Sinha and colleagues, in their 2020 review in Translational Andrology and Urology, reviewed sermorelin, ipamorelin, and related GH secretagogues as adjuncts for body composition management in hypogonadal men, not as testosterone replacements, noting that all reviewed compounds were potent GH and IGF-1 stimulators that may improve body composition while "a paucity of data examining the clinical effects of these compounds currently limits our understanding." The relevance of GH secretagogues to the peptides vs. TRT question is narrow: they may address specific body composition endpoints that testosterone alone does not fully resolve. GH secretagogues are not substitutes for testosterone management, and any multi-compound approach should be evaluated individually by a qualified provider. Evidence grade: [Human observational; limited RCT data for individual compounds].

Side-by-Side Safety Comparison

The following comparison covers compound classes and general risk profiles, not individual products. Specific products within each class, and individual patient characteristics, may differ significantly. Both sides of the comparison reflect the best available evidence; neither is selectively graded.

Kisspeptin is included in this comparison as an investigational compound with mechanistic and small-N clinical evidence relevant to the HPG axis. It has no FDA-approved indication, no commercial product, and no lawful prescribing pathway for hypogonadism outside a registered clinical trial; it is not currently a clinical treatment option for routine hypogonadism management.

• HPG axis suppression
  • TRT: Predictable, well-documented suppression of LH and FSH through negative feedback. Testicular atrophy and impaired spermatogenesis occur during use. Recovery after cessation possible but not guaranteed. [Human RCT]
  • Peptide-based HPG stimulants (gonadorelin, kisspeptin, enclomiphene): These approaches are designed to preserve or stimulate the HPG axis; LH and FSH are maintained or elevated during use. No documented axis suppression at therapeutic doses. [Human RCT, Phase 2 data; limited long-term data]
• Cardiovascular adverse events
  • TRT: Non-inferior to placebo for MACE in the 5,246-person TRAVERSE trial (HR 0.96; 95% CI 0.78–1.17). Elevated secondary signals: atrial fibrillation and pulmonary embolism. Current consensus does not support major CV harm in appropriately selected patients. [Human RCT, largest available trial]
  • Peptide-based HPG stimulants: No large RCT cardiovascular safety data exists for any peptide HPG stimulant as a hypogonadism treatment. CV risk profile is not characterized. [Insufficient data]
• Erythrocytosis
  • TRT: Well-documented hematological risk. The Jones et al. 2015 review found a 315% greater risk compared to untreated controls. 23% of a 247-patient cohort reached hematocrit above 0.50. Frequency: Common (with higher rates for injectable formulations). [Human observational]
  • Peptide-based HPG stimulants: Erythrocytosis has not been a reported signal in the limited published data on these compounds; however, surveillance is limited and long-term hematological effects are not characterized. Frequency: Unknown (insufficient data). [Insufficient data]
• Fertility preservation
  • TRT: Impairs spermatogenesis through LH/FSH suppression. Recovery is possible but requires cessation and may require pharmacological intervention. Fertility impact is a predictable consequence of HPG axis suppression. [Human observational / Human RCT]
  • Peptide-based HPG stimulants: Designed to preserve or restore LH, FSH, and spermatogenesis. Phase 2 enclomiphene data specifically demonstrated sperm count preservation versus testosterone gel. Gonadorelin is used clinically for fertility preservation in TRT users. [Human RCT, Phase 2; Human observational]
• Prostate safety
  • TRT: Meta-analysis of 28 RCTs (N = 3,461) found no statistically significant adverse effects on prostate volume or urinary function, with PSA at the margin of significance (p=0.06). Active prostate cancer remains a contraindication. [Human RCT]
  • Peptide-based HPG stimulants: No large-scale prostate safety data. Theoretical androgenic stimulation concern exists if testosterone rises to high-normal or supranormal levels. [Insufficient data]
• Long-term safety data
  • TRT: Decades of observational data; multiple Phase 3 RCTs including TRAVERSE (33 months); evidence synthesis covering 5,601 participants. Longest characterized safety record of any approach discussed here. [Human RCT / Human observational]
  • Peptide-based HPG stimulants: Phase 2 RCTs only; no multi-year safety cohort data; long-term adverse event profiles not characterized. [Human RCT, Phase 2; data gaps substantial]
• Regulatory and prescribing status (as of April 2026)
  • TRT: FDA-approved prescription medications available in multiple formulations (injectable, topical, oral, subcutaneous pellet). Prescribing information establishes contraindications, monitoring requirements, and drug interactions. Available through licensed prescribers.
  • Controlled-substance status: Testosterone and its esters are Schedule III controlled substances under the Anabolic Steroid Control Act of 1990 (21 U.S.C. § 802(41)). Prescribers must hold an active DEA registration; prescriptions are subject to refill limits and state prescription drug monitoring program reporting. Peptide-based HPG stimulants (gonadorelin, kisspeptin, enclomiphene) are not controlled substances.
  • Peptide-based HPG stimulants: Gonadorelin (previously FDA-approved as Factrel/Lutrepulse, since discontinued) is on FDA's Category 1 503A bulk drug substances list and available through compounding pharmacies; status is subject to ongoing rulemaking. Enclomiphene has never been FDA-approved (two Complete Response Letters in 2015 and 2016) and is available through compounding pharmacies under Section 503A; the racemic parent clomiphene citrate is FDA-approved for female ovulation induction only. Kisspeptin is investigational with no approved indication and no commercial product. Availability and lawful prescribing pathways vary by compound and clinical context.

This comparison covers classes and general profiles. An individual TRT protocol with proper monitoring and appropriate patient selection differs materially from an unsupervised or unmonitored one. Similarly, a peptide-based approach supported by Phase 2 trial data (enclomiphene) carries a different evidence weight than one with only mechanistic or single-study data (kisspeptin for hypogonadism). The comparison is useful for understanding where the evidence is and where the gaps are; it does not replace individual clinical evaluation.

Who Should Not Use These Approaches Without Provider Evaluation

The following groups face elevated risk or require specific clinical considerations for either approach. This is not a complete contraindication list for any specific product; consult prescribing information and a qualified provider for compound-specific guidance.

• Men who have not completed family planning: TRT suppresses spermatogenesis in a predictable and potentially prolonged way. This is not a theoretical risk; it is a pharmacological consequence of exogenous testosterone use. Any man who may want biological children should discuss this with a provider before initiating TRT. HPG-stimulating approaches preserve the axis but also require provider oversight. [Human observational / Human RCT]
• Men with cardiovascular disease or elevated CV risk: The TRAVERSE trial specifically enrolled men with elevated cardiovascular risk. Its non-inferiority finding applies to a supervised clinical trial context with monitoring. Signals for atrial fibrillation and pulmonary embolism in the testosterone group require individual risk assessment. [Human RCT]
• Men with elevated baseline hematocrit: TRT-induced erythrocytosis is more likely in those with baseline hematocrit at the upper end of normal. A pre-treatment hematocrit measurement is an essential screening step. [Human observational]
• Men with active or suspected hormone-sensitive malignancy: Active prostate cancer is a contraindication to TRT in current guidelines. GH secretagogue use carries theoretical concern regarding IGF-1 and proliferative signaling; this is not established at therapeutic doses but requires provider evaluation. [Guideline-based; theoretical for GH secretagogues]
• Men with sleep apnea: Testosterone can worsen obstructive sleep apnea, as noted in TRT prescribing information. Evidence grade: [Human observational, prescribing information]
• Men using unregulated peptide sources: Peptides sold outside FDA-regulated pharmacy channels carry contamination, incorrect dosing, and misidentification risks. There is no way to distinguish compound effects from contaminant effects without pharmaceutical-grade sourcing and controlled study conditions. [Human observational]
• Competitive or drug-tested athletes: All compounds discussed in this article (testosterone and its esters, gonadorelin, kisspeptin, enclomiphene, and GH secretagogues) are listed on the World Anti-Doping Agency (WADA) Prohibited List. Athletes subject to sport-governing-body testing should consult their sport's anti-doping rules and therapeutic use exemption (TUE) process before any use.

Drug Interactions and Combination Considerations

Drug interaction data for TRT is established in FDA-approved prescribing information. For peptide-based HPG stimulants, interaction data is limited to mechanistic inference and smaller clinical studies.

TRT interactions

• Insulin and antidiabetic agents: Testosterone improves insulin sensitivity; concurrent use may require monitoring and potential dose adjustment of antidiabetic medications. Evidence grade: [Human RCT, prescribing information]
• Anticoagulants (warfarin): Testosterone may potentiate the anticoagulant effects of warfarin; INR monitoring is recommended in patients on concurrent anticoagulation. Evidence grade: [Human observational, prescribing information]
• Corticosteroids: Concurrent corticosteroid use may increase fluid retention risk with TRT. Evidence grade: [Human observational, prescribing information]

HPG-stimulating peptide interactions

• Concurrent gonadotropin therapy: Gonadorelin used alongside exogenous gonadotropins (hCG, FSH) requires provider oversight to avoid excessive HPG stimulation; no formal interaction data in prescribing-information format exists. Kisspeptin is investigational and not prescribed outside registered clinical trials; theoretical interaction considerations are not established in any prescribing framework. Evidence grade: [Human observational, mechanistic]
• Estrogen-active compounds: Enclomiphene's mechanism depends on blocking hypothalamic estrogen receptors; concurrent use of estrogen-active compounds or aromatase inhibitors could theoretically alter its effectiveness. Evidence grade: [Pharmacological mechanism, insufficient clinical data]

This is not an exhaustive interaction list. Before starting any hormonal or peptide therapy, provide your healthcare provider with a complete list of all medications, supplements, and over-the-counter products you use.

When to Seek Medical Attention

Not every effect from hormone optimization requires an emergency visit. The following triage distinguishes symptoms that need immediate care from those warranting a provider call from those that are expected and monitorable.

Seek immediate emergency care

• Signs of pulmonary embolism: sudden shortness of breath, chest pain, rapid heart rate, or coughing blood. This is particularly relevant given the elevated pulmonary embolism signal in the TRAVERSE testosterone group. Call 911.
• Signs of severe allergic reaction to any injection: hives spreading rapidly, swelling of face or throat, difficulty breathing, sudden drop in blood pressure. Call 911.
• Chest pain or palpitations following testosterone injection or any injectable peptide, particularly in men with pre-existing cardiovascular risk.
• Priapism (erection lasting more than 4 hours), a listed warning in TRT prescribing information requiring immediate care.

Contact your provider within 24–48 hours

• Worsening sleep apnea symptoms after TRT initiation: new or worsened snoring, apneic episodes, or daytime fatigue consistent with disrupted sleep.
• Mood changes, irritability, or emotional lability persisting beyond the first two weeks of any hormone-affecting therapy.
• Leg swelling, pain, or redness that could suggest deep vein thrombosis; relevant given VTE signal considerations with TRT.
• Headache, visual disturbances, or new neurological symptoms; particularly relevant with enclomiphene (clomiphene class visual effects) and requiring prompt evaluation.
• Injection site reactions that do not resolve within 72 hours or that show spreading redness, warmth, or discharge.
• Any self-modification of dose or frequency without provider guidance. Follow up promptly after any unilateral dosing change.

Expected effects: monitor but not urgent

• Mild acne in the first weeks of TRT, a common androgenic effect generally manageable with skin hygiene; discuss with provider if persistent or severe.
• Transient testicular volume reduction with TRT, a predictable consequence of HPG axis suppression; expected and not an emergency.
• Mild injection site tenderness or small nodule resolving within 24–72 hours, the most common injectable peptide side effect.
• Mild fluid retention in the first weeks of TRT, typically self-limiting at appropriate doses; report to provider if significant or accompanied by cardiovascular symptoms.

Peptides Obtained Outside Regulated Channels: the Sourcing Caveat

Peptides sold through online vendors as "research use only" or "not for human use" are not regulated by the FDA for quality, purity, or potency. Side effects reported from these products may be caused by the compound, by contaminants, by incorrect dosing, or by misidentified ingredients. Colalto, writing in Regulatory Toxicology and Pharmacology in 2024, noted that impurities in therapeutic peptide products can cause adverse reactions at doses that would otherwise be tolerable. There is no way to distinguish these causes without pharmaceutical-grade sourcing and controlled conditions. This limitation applies to all peptides in this comparison that are not obtained through licensed pharmacy channels.

Which Biomarkers Can Help Monitor Safety?

Tracking relevant biomarkers before and during any hormonal therapy provides objective data for you and your provider to distinguish expected effects from adverse ones. Without a pre-treatment baseline, changes detected during or after use cannot be confidently attributed to the therapy rather than to pre-existing trends. The following markers are clinically relevant to safety monitoring for both TRT and peptide-based approaches.

• Total and free testosterone: The primary therapeutic target for either approach. Establishes the pre-treatment deficit and monitors whether the therapy is achieving the intended hormonal effect without supranormal elevation. Total testosterone and free testosterone together give the most clinically complete picture.
• LH and FSH: The HPG axis markers that distinguish secondary hypogonadism from primary hypogonadism, and that confirm whether an HPG-stimulating approach is activating the axis appropriately versus whether TRT is producing expected axis suppression. Luteinizing hormone and follicle-stimulating hormone are both relevant at baseline and on follow-up.
• Hematocrit and hemoglobin: The primary safety markers for TRT-induced erythrocytosis. Monitoring hematocrit at baseline and at 3, 6, and 12 months is standard of care during TRT. Evidence grade for monitoring: [Human RCT / Prescribing information standard]
• PSA (prostate-specific antigen): Baseline PSA is standard practice for men over 40 or with prostate risk factors before TRT initiation. Total PSA provides a reference point for any subsequent monitoring.
• Estradiol: Testosterone aromatizes to estradiol; monitoring estradiol levels during TRT identifies excessive aromatization, which can contribute to gynecomastia, mood effects, and fluid retention. Estradiol tracking is also relevant during enclomiphene use, which modulates estrogen receptor signaling.
• SHBG (sex hormone-binding globulin): Determines the fraction of testosterone that is biologically available. SHBG levels affect interpretation of total testosterone measurements and influence dosing decisions in TRT. Elevated SHBG explains why some men with normal total testosterone remain functionally hypogonadal.
• IGF-1: The primary readout of GH axis activity. Relevant for any co-administration of GH secretagogues alongside TRT or HPG stimulants. Monitoring IGF-1 levels establishes whether GH axis stimulation is within the physiological range or trending toward supraphysiological levels associated with carpal tunnel syndrome, edema, and insulin resistance. Evidence grade for monitoring: [Human RCT, GH secretagogue trials]
• Fasting glucose and HbA1c: GH secretagogues reduce insulin sensitivity at supraphysiological doses; TRT may improve insulin sensitivity in hypogonadal men. Either direction of change warrants a metabolic baseline for interpretation. Evidence grade: [Human RCT]
• Lipid panel (total cholesterol, HDL, LDL, triglycerides): TRT has neutral-to-modest lipid effects in trial data; GH secretagogues may affect triglycerides. A lipid baseline captures pre-existing cardiovascular risk context and enables detection of any compound-related changes.
• hs-CRP: Systemic inflammation marker. Provides cardiovascular and systemic context before starting any hormonal therapy. Elevated hs-CRP at baseline may influence treatment decisions in men with cardiovascular risk.

Understanding Your Baseline

Before starting any hormonal therapy, whether TRT or a peptide-based alternative, knowing your baseline metabolic, hormonal, and organ function markers gives you and your provider a reference point. Without pre-treatment values, changes detected during or after use cannot be confidently attributed to the therapy rather than to pre-existing trends. This is particularly important for markers where TRT has documented effects (hematocrit, estradiol, HPG axis hormones) and for markers where the evidence base for peptide effects remains incomplete.

That principle, establishing the data before evaluating any intervention, is foundational to Superpower's approach to preventive health. Whether you are starting an FDA-approved testosterone formulation or exploring a peptide-based approach to hormonal optimization, baseline biomarker values are the difference between informed and uninformed risk assessment.

IMPORTANT SAFETY INFORMATION

This article discusses peptides as a class and testosterone replacement therapy. Individual compounds vary significantly in regulatory status, safety profile, and clinical evidence. Some compounds discussed are FDA-approved prescription medications; others are available only through compounding pharmacies; others are not approved for human use in the United States. This content does not constitute medical advice for any specific compound or clinical situation.

Do not start, stop, or modify any hormonal or peptide therapy without consulting a qualified healthcare provider who can evaluate your individual medical history, current medications, hormonal baseline, and health goals.

Testosterone replacement therapy is a prescription medication. FDA-approved formulations require a prescription from a licensed healthcare provider. Testosterone is a Schedule III controlled substance under federal law (Anabolic Steroid Control Act of 1990; 21 U.S.C. § 802(41)) and is subject to DEA prescribing controls and state-level prescription drug monitoring program reporting. Prescribers must hold an active DEA registration; prescriptions are subject to refill limits under 21 CFR § 1306.22 (no more than five refills within 6 months from the date of issuance) and state PDMP reporting. Telehealth prescribing of testosterone is additionally governed by the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 (21 U.S.C. § 829(e)) and DEA's current telemedicine-controlled-substance rulemaking; evaluation requirements vary by state and by the prescriber's credentialing context. Testosterone has contraindications including active prostate cancer, male breast cancer, and hypersensitivity to the compound. Full prescribing information for approved testosterone formulations is available at dailymed.nlm.nih.gov.

Peptide compounds discussed in this article have varying legal and regulatory statuses as of April 2026. Gonadorelin (previously FDA-approved as Factrel and Lutrepulse before commercial discontinuation) is on FDA's Category 1 503A bulk drug substances list (status subject to ongoing rulemaking) and is available through licensed compounding pharmacies under § 503A. Enclomiphene has never been FDA-approved for any indication; its developer received two Complete Response Letters (2015, 2016). It is available through § 503A compounding as a non-FDA-approved substance, not as an off-label use of an approved drug. Kisspeptin has no approved therapeutic product in the United States and is investigational. Among GH secretagogues, ipamorelin and CJC-1295 are FDA Category 2 bulk substances without a sanctioned § 503A compounding pathway; sermorelin's compounding status is historically ambiguous because its prior FDA-approved form (Geref) was discontinued and FDA has not formally placed sermorelin on the § 503A bulks list. For current regulatory information, see fda.gov.

If you are using a peptide obtained from an unregulated source, be aware that product quality, purity, and accuracy of dosing cannot be verified without pharmaceutical-grade standards. Contaminated or mislabeled products may cause adverse effects not described in the clinical literature for the intended compound.

If you experience symptoms consistent with a serious adverse event (pulmonary embolism signs including sudden shortness of breath and chest pain, severe allergic reaction, priapism lasting more than 4 hours, or signs of infection at an injection site), seek emergency medical care immediately.

Disclaimer: This page is provided by Superpower Health for educational and informational purposes only. This content does not constitute medical advice. Always consult a qualified healthcare provider.